Zhao XY, Yu TT, Liu S, Liu YJ, Liu JJ, Qin J. Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats. World J Diabetes 2020; 11(12): 611-621 [PMID: 33384768 DOI: 10.4239/wjd.v11.i12.611]
Corresponding Author of This Article
Jie Qin, MD, Chief Doctor, Department of Endocrinology, Shanxi Provincial People's Hospital, No. 29 Shuangtasi Street, Taiyuan 030012, Shanxi Province, China. bxl5cnfmsys@163.com
Research Domain of This Article
Research & Experimental Medicine
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xuan-Ye Zhao, Ting-Ting Yu, Sheng Liu, Yao-Ji Liu, Jing-Jin Liu, Jie Qin, Department of Endocrinology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China
Author contributions: Qin J designed the research study; Zhao XY performed the research and wrote the manuscript; Yu TT and Liu S contributed to the purchase of new reagents and analytic tools; Liu YJ and Liu JJ analyzed the data; all authors have read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Shanxi Provincial People's Hospital.
Institutional animal care and use committee statement: All animal experiments were approved by the Medical Ethics Committee of Shanxi Provincial People's Hospital.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Qin, MD, Chief Doctor, Department of Endocrinology, Shanxi Provincial People's Hospital, No. 29 Shuangtasi Street, Taiyuan 030012, Shanxi Province, China. bxl5cnfmsys@163.com
Received: August 10, 2020 Peer-review started: August 10, 2020 First decision: September 21, 2020 Revised: September 28, 2020 Accepted: October 21, 2020 Article in press: October 21, 2020 Published online: December 15, 2020 Processing time: 124 Days and 21.1 Hours
ARTICLE HIGHLIGHTS
Research background
Liraglutide is beneficial to the kidneys in diabetics, but its exact role in the kidney is unclear.
Research motivation
To provide a new idea for the treatment of diabetes and diabetic nephropathy.
Research objectives
The study was to investigate the specific effects of liraglutide on the kidney.
Research methods
To explore the effect of liraglutide on the kidney of rats with type 2 diabetes by establishing a rat model of type 2 diabetes
Research results
The mechanism of the treatment of diabetic nephropathy with liraglutide is probably related to the reduction of ER stress.
Research conclusions
This study indicated that liraglutide may delay the progression of diabetic nephropathy by reducing endoplasmic reticulum stress, and the effect of liraglutide on renal protection is dose-dependent.
Research perspectives
The role of liraglutide may provide new ideas for the treatment of diabetic nephropathy.
